Using ALBI score at the start of sorafenib treatment to predict regorafenib treatment candidates in patients with hepatocellular carcinoma
Atsushi Yukimoto(Ehime University), Yoichi Hiasa(Ehime University Hospital), Masashi Hirooka(Ehime University), Kojiro Michitaka(Ehime Prefectural Central Hospital), Masanori Abe(Ehime University), Kouji Joko(Matsuyama Red Cross Hospital), Yusuke Imai(Ehime University), Yohei Koizumi(Ehime University), Takao Watanabe(Miyoshi Kasei (Japan)), Hironori Ochi, Osamu Yoshida(Ehime University Hospital), Atsushi Hiraoka(Ehime Prefectural Central Hospital)
Cited by 35
Related Papers
Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors
|Oncogene|1999|693
Evidence-based clinical practice guidelines for Liver Cirrhosis 2020
|Journal of Gastroenterology|2021|424
A Glycine-rich RNA-binding Protein Mediating Cold-inducible Suppression of Mammalian Cell Growth
|The Journal of Cell Biology|1997|388
Detection of urovirulence factors in<i>Escherichia coli</i>by multiplex polymerase chain reaction
|FEMS Immunology & Medical Microbiology|1995|317
Genetic Evidence Supporting the Fecal-Perineal-Urethral Hypothesis in Cystitis Caused by Escherichia Coli
|The Journal of Urology|1997|281